Uterine fibroids are a highly prevalent condition impacting nearly 95 million people worldwide. While in some cases it can remain asymptomatic, symptomatic presentation, ranging from heavy menstrual bleeding and anemia to cramping, dyspareunia, and infertility, can result in significant negative impacts on quality of life and sexual function for affected patients. In addition, this condition also affects the US healthcare system, costing approximately $34 billion annually. It is imperative that clinicians recognize the consequential effects that uterine fibroids can have on both individual patients as well as the healthcare system as a whole.
In the first activity of this CME Outfitters Snack series, expert faculty will highlight the economic and individual impacts of uterine fibroids as well as guide learners through the diagnostic process and management of this condition with a goal of reducing disparities.
Evaluate the impact of uterine fibroids on both patients and the health care system.
Supported by an educational grant from Pfizer Inc. and Sumitomo Pharma America.
Obstetrician-gynecologists, primary care physicians, nurse practitioners (NPs), physician associates (PAs), and nurses.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Al-Hendy reports the following financial relationships:
Consultant: AbbVie Inc.; Bayer; Myovant Sciences; Norvartis Pharmaceuticals Corporation; ObsEva; and Pfizer Inc.
Research Support: CrilaHealth
Dr. Powell reports no financial relationships to disclose.
Ms. Valbrun reports the following financial relationships:
Consultant: Myovant Sciences/Pfizer Inc.
Grants: (Paid to The White Dress Project) Ferring Pharmaceuticals; Gynesonics; Hologic, Inc.; and Myovant Sciences/Pfizer Inc.
Speakers Bureau: Myovant Sciences/Pfizer Inc.
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
• Shirley Michelle Franks, MSN, APRN, FNP-BC (peer reviewer)
• Morgan Stockberger, MD (planning committee)
• Jessica Whelan, DNP, APRN, FPMHNP-BC, RN-BC (planning committee)
• Susan H. Yarbrough, CHCP (planning committee)
• Sandra Caballero, PharmD (planning committee)
• Sharon Tordoff (planning committee)
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).